Home

Insights

Jubilant Pharmova Ltd P/E Ratio

Jubilant Pharmova Ltd P/E Ratio

download
stocks purchased

₹ 3.4 Cr

Volume transacted

stocks purchased

47.9 K

stocks traded

Image

Jubilant Pharmova Ltd

NSE: JUBLPHARMA

PE

290.2

Last updated : 21 May 11:04 AM

Key Highlights

    The P/E Ratio of Jubilant Pharmova Ltd is 290.2 as of 21 May 11:04 AM .a1#The P/E Ratio of Jubilant Pharmova Ltd changed from 18.4 on March 2019 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years. a1#The Latest Trading Price of Jubilant Pharmova Ltd is ₹ 703.45 as of 21 May 16:01 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 27.2. The PE Ratio of Finance industry is 13.6. The PE Ratio of IT - Software industry is 27.9. The PE Ratio of Pharmaceuticals industry is 27.7. The PE Ratio of Retail industry is 94.8. The PE Ratio of Textiles industry is 21.1. In 2023a1#The Market Cap of Jubilant Pharmova Ltd changed from ₹ 10580 crore on March 2019 to ₹ 4445 crore on March 2023 . This represents a CAGR of -15.92% over 5 years. a1#The Revenue of Jubilant Pharmova Ltd changed from ₹ 1463 crore to ₹ 1726 crore over 7 quarters. This represents a CAGR of 9.91% a1#The EBITDA of Jubilant Pharmova Ltd changed from ₹ 203.6 crore to ₹ 266.9 crore over 7 quarters. This represents a CAGR of 16.73% a1#The Net Profit of Jubilant Pharmova Ltd changed from ₹ 46.8 crore to ₹ 66.4 crore over 7 quarters. This represents a CAGR of 22.13% a1#The Dividend Payout of Jubilant Pharmova Ltd changed from 48.56 % on March 2019 to 159.68 % on March 2023 . This represents a CAGR of 26.88% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1918.4
Mar '204.4
Mar '2113
Mar '2214.9
Mar '230

Fundamental Metrics

Market Cap

11,417 Cr

EPS

2.4

P/E Ratio (TTM) *

290.2

P/B Ratio (TTM) *

2.0

Day’s High

718.85

Day’s Low

664.05

DTE *

0.7

ROE *

-0.8

52 Week High

740.8

52 Week Low

318.5

ROCE *

2.9

* All values are consolidated

* All values are consolidated

Image

Jubilant Pharmova Ltd

NSE: JUBLPHARMA

PRICE

703.45

-13.30(-1.86%)

stock direction

Last updated : 21 May 16:01

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Jubilant Pharmova Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

2

T

BlinkX Score for Jubilant Pharmova Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value

Market Value

10,955

Asset Value

3,990

1.7 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

37 Cr

290.2 X

PE Ratio

Market Cap

₹10955Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

37 Cr

290.2 X

PE Ratio

Market Cap

₹10955Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Jubilant Pharmova Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Jubilant Pharmova Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Jubilant Pharmova Ltd's Share Price stands at 703.45. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-05-21T16:01:00 is 2.37. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 703.45/ 2.37= 290.17.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Jubilant Pharmova Ltd's stock is trading at approximately 290.17 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Jubilant Pharmova Ltd’s PE Ratio (BSE: JUBLPHARMA)

    The Price-to-Earnings (PE) ratio, used to assess Jubilant Pharmova Ltd's stock (BSE: JUBLPHARMA), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '1910581
Mar '203964
Mar '2110839
Mar '226178
Mar '234445

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '221463
Sep '221613
Dec '221562
Mar '221699
Jun '231596
Sep '231699
Dec '231726

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '22204
Sep '22172
Dec '22154
Mar '22240
Jun '23177
Sep '23261
Dec '23267

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '2247
Sep '225
Dec '22-16
Mar '22-100
Jun '236
Sep '2362
Dec '2366

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1949
Mar '2025
Mar '2137
Mar '22101
Mar '23160

* All values are a in %

About Jubilant Pharmova Ltd

About Jubilant Pharmova Ltd

    The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs. The contract research and development segment provides drug discovery and development services as well as clinical data software and service solutions. . also in the same year, the company had formed marketing subsidiary in the USA and acquired acetyl plant in western India. The business has been transferred on a going concern basis as a slump sale, which will enable it to focus on its core businesses in Pharmaceuticals and Life Sciences. In 2014-15, the company completed the consolidation of all its Pharmaceutical business under Jubilant Pharma, Singapore with effect from July 1, 2014. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area. The research for the project, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (India) and some parts at Jubilant Discovery Center, USA. The milestone reflects the successful transition of a collaborative program to the next phase in the discovery and development process. Jubilant Biosys will continue to apply its effective integrated drug discovery platform to generate novel molecules that can demonstrate clinical proof-of-mechanism. It manufactured 3 new CDMO intermediates for US and Japan innovator companies which were 100% On-Time and In-Full (OTIF) due to improved system procedures. During the year 2022, the Company commissioned the state-of-the-art Chemistry Innovation Research Centre at Greater Noida, India to double the chemistry research capacity.

Jubilant Pharmova Ltd News Hub

News

Jubilant Pharmova announces conclusion of Montreal facility audit by US FDA

The said facility is operated by Jubilant Draximage Inc., a subsidiary of Jubilant Pharma ...

Read more

25 Apr 2024 10:43

News

Jubilant Pharmova Ltd leads losers in 'A' group

Tata Communications Ltd, Ion Exchange (India) Ltd, CRISIL Ltd and Neuland Laboratories Ltd...

Read more

19 Apr 2024 15:00

News

Jubilant Cadista Pharmaceuticals to close down manufacturing operations

Jubilant Pharmova announced that the company's subsidiary, Jubilant Cadista Pharmaceutical...

Read more

18 Apr 2024 09:12

News

Jubilant Pharmova jumps as USFDA classifies Roorkee facility as VAI

Jubilant Generics (JGL) is subsidiary of Jubilant Pharma, which is wholly owned subsidiary...

Read more

18 Apr 2024 13:19

News

Jubilant Generics' Roorkee unit clears USFDA inspection

Jubilant Pharmova's wholly owned subsidiary Jubilant Pharma, today announced that its subs...

Read more

17 Apr 2024 17:50

News

Board of Jubilant Pharmova appoints directors

The Board of Jubilant Pharmova at its meeting held on 26 March 2024 has approved the appoi...

Read more

26 Mar 2024 13:40

Product Composition by Percentage (Revenue)

Document

Annual Reports

Annual Report 2023

dropdown
download

Credit Ratings

Credit Report 2022

dropdown
download

Concalls

Feb 2024

PPT

Oct 2023

PPT

July 2023

PPT

May 2023

PPT

Feb 2023

Transcript

Aug 2022

Transcript

June 2022

Transcript

Mar 2022

PPT

Jan 2022

Transcript

July 2021

Transcript

June 2021

TranscriptPPT

Jan 2021

Transcript

Nov 2020

Transcript

Sep 2020

Transcript

June 2020

TranscriptPPT

Jan 2020

Transcript

Feb 2024

PPT

Oct 2023

PPT

July 2023

PPT

May 2023

PPT

Feb 2023

Transcript

Aug 2022

Transcript

June 2022

Transcript

Mar 2022

PPT

Jan 2022

Transcript

July 2021

Transcript

June 2021

TranscriptPPT

Jan 2021

Transcript

Nov 2020

Transcript

Sep 2020

Transcript

June 2020

TranscriptPPT

Jan 2020

Transcript

FAQs for PE of Jubilant Pharmova Ltd

What is Jubilant Pharmova Ltd current share price?

The current market price of Jubilant Pharmova Ltd as of May 21, 2024 is ₹703.45.

Is Jubilant Pharmova Ltd a good investment?

As per BlinkX Score Jubilant Pharmova Ltd scores 1 in Revenue, 17 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Jubilant Pharmova Ltd's total net assets?

According to Jubilant Pharmova Ltd's most recent financial filings, the company's net assets total ₹3989.8 Cr.

Is Jubilant Pharmova Ltd making a profit or loss?

Jubilant Pharmova Ltd's net Profit as of May 21, 2024 is close to ₹37 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199